Shares of Phoenix Asia Holdings Limited (PHOE) are trading slightly higher on Thursday, up 0.19%, after the company announced a $1 billion stock acquisition of ACEA Therapeutics, Inc. The move marks a significant expansion beyond its core construction business into the pharmaceutical sector.
The deal, agreed on May 5, involves Phoenix Asia purchasing 100% of ACEA Pharma's equity through the issuance of 100 million newly-issued ordinary shares at $10.00 each. The acquisition is expected to close by the end of the second quarter of 2026, subject to regulatory and stock exchange approvals.
This comes on a mixed day for the broader market: the Nasdaq is up 0.57% and the S&P 500 is up 0.14%, while the Dow Jones and Russell 2000 are slightly down. Technology stocks are leading the gainers, which may be supporting Phoenix Asia's stock despite some sector declines.
Phoenix Asia operates primarily through its indirectly wholly-owned subsidiary, focusing on substructure works in Hong Kong, including site formation, ground investigation, and foundation work. It also provides structural steelworks and other construction services. The ACEA Pharma acquisition is a strategic pivot that could open new revenue streams and market opportunities in the pharmaceutical industry.
According to MarketDash Edge rankings, Phoenix Asia shows strong momentum with a score of 99.45, indicating it is outperforming the broader market. However, its value score is weak at 0.64, suggesting the stock trades at a steep premium relative to peers. The verdict: this is a momentum-driven story, but investors should weigh the strong momentum against valuation risks.
At the time of publication, PHOE shares were trading at $28.66.
